UPDATE: Brean Capital Assumes Neuralstem (CUR) at Buy

(Updated - October 4, 2016 10:14 AM EDT)

Brean Capital assumed coverage on Neuralstem (NASDAQ: CUR) with a Buy rating and a price target of $4.00.

Analyst Jason Wittes said, "The company is currently enrolling a Phase II (n=220) trial for NSI-189 which is a novel neurogenic small molecule targeting Major Depressive Disorder (MDD) and may have the potential to be a neuro-regenerative drug in reversing diabetic neuropathies given the recent preclinical data. We expect a read out of this trial in 2H17—already 50% enrolled. Recently the company secured an additional $20 million through a Tianjin Pharmaceutical Holding Group for completion of the Phase II trial. Assuming the Phase II is successful, we expect NSI-189 will have no problem finding a partner to fund a Phase III study, especially if results continue to show duration, improved cognition and enhanced potentiation. The company is also developing a stem cell platform, which it looks to fund externally."

For an analyst ratings summary and ratings history on Neuralstem click here. For more ratings news on Neuralstem click here.

Shares of Neuralstem closed at $0.31 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• B.Riley Starts Okeanis Eco Tankers Corp (ECO) at Buy, 'solid competitive advantage'
• Evercore ISI Starts NXP Semiconductors NV (NXPI) at Outperform, 'Blue Chip Auto Play'
• JPMorgan Starts Auna SA (AUNA) at Overweight, 'Buying LatAm Healthcare Growth at Discounted Terms'